Rimegepant 75 mg for acute treatment of migraine is associated with significant reduction in monthly migraine days: Results from a long-term, open-label study

• मुख्य लेखकों: Gilbert L'Italien (लेखक), Evan Popoff (लेखक), Karissa Johnston (लेखक), Donnie McGrath (लेखक), Charles M Conway (लेखक), Lauren Powell (लेखक), Linda Harris (लेखक), Nicole Kowalczyk (लेखक), Robert Croop (लेखक), Vladimir Coric (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: SAGE Publishing, 2022-01-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Background: Rimegepant, a small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonist, is approved for the acute and preventive treatment of migraine. We hypothesized that intermittent CGRP receptor blockade with rimegepant 75 mg acute treatment as needed (PRN) might result in red...